‘Cell or Not to Cell’ that is the Question: For Intervertebral Disc Regeneration?

Thorpe AA1, Sammon C1 and Le Maitre CL1*

1Head of Musculoskeletal Research Group, Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield, UK
2Materials and Engineering Research Institute, Sheffield Hallam University, Sheffield, UK

Abstract

Low back pain, strongly associated with intervertebral disc degeneration, is one of the most prevalent health problems in the western world today. Current treatments have been directed toward alleviating patient symptoms but have been shown to accelerate degenerative changes in adjacent discs. New approaches in tissue engineering have provided a variety of treatment options including the delivery of regenerative cells, either alone or together with hydrogel scaffolds in order to restore/maintain disc biomechanics whilst simultaneously regenerating the matrix. This review paper discusses the use of cellular and acellular therapeutic strategies for IVD degeneration with an emphasis on the importance of tailoring the treatment strategy with stage of degeneration, thus offering insight into the future clinical options for IVD regeneration.

Keywords: Biomaterials; Intervertebral disc; Regeneration; Stem Cells

Anatomy of the Intervertebral Disc

The Human Intervertebral Disc (IVD) is a fibrocartilaginous structure positioned between each connecting vertebra of the spinal column. Mechanically, the IVD transmits load, arising from body weight and muscle activity, and permits a range of spinal movement including bending, flexion and torsion [1]. The normal IVD is composed of three morphologically distinct regions: the Cartilaginous End Plates (CEP), the highly organised Annulus Fibrosus (AF) and the central gelatinous Nucleus Pulposus (NP), which operate collectively to mechanically transfer loads and disperse energy evenly throughout the spine. The CEP is a layer of hyaline cartilage which separates the AF and NP from the adjacent vertebral body and facilitates diffusion of nutrients and oxygen to the avascular internal structures of the IVD [2,3]. The AF can be further subdivided into the outer and the inner AF. The outer AF contains large amounts of fibrous collagen type I orientated into lamellae, providing resistance to tensile forces from bending and twisting of the vertebral column [4]. The inner AF is a transition zone between the randomly organised, hydrated NP and the highly organised, fibrous outer AF, with characteristics of both tissue types observed in this region. The NP has a gelatinous matrix composed of randomly arranged collagen type II fibres, radially arranged elastin fibres and small amounts of collagen types VI, IX and XI, all of which are embedded in a highly hydrated matrix rich in proteoglycans (mainly aggrecan) [5]. The hydrated proteoglycans provide viscoelasticity and resistance to compression whilst the collagen crosslinks confer tensile strength [6].

Cell Types Present in the Normal IVD

The cells which reside in the NP and AF are morphologically and phenotypically distinct. At maturity the AF contains elongated fibroblast like cells at a cell density of approximately 9 x 10^6 cells/cm^3 [7]. At birth NP cells display large (25-85 µm) vacuolated morphology with distinct resemblance to the embryonic notochordal cells from which they are assumed to originate [8-10]. During maturation the population of large vacuolated cells within the NP decreases and becomes replaced by smaller, round and non-vacuolated chondrocyte like cells at a cell density of approximately 4 x 10^6 cells/cm^3[7,10,11]. The origin of these smaller chondrocyte like cells in the NP is currently an unresolved area of IVD research with controversy as to whether the chondrocyte like cells migrate from surrounding tissues or differentiate from the notochordal cells [12,13]. Furthermore a definitive phenotypic maker of NP cells is yet to be characterised, thus the origin and profile of these cells remains a significant challenge for cell based regenerative strategies [14-18].

Degeneration of the IVD

Degeneration of the IVD is characterised by progressive changes in the Extracellular Matrix (ECM) due to altered cell metabolism, matrix synthesis and an increase in degradation of normal matrix components [19,20]. As IVD degeneration advances collagen type II in the NP is gradually replaced by the more fibrous collagen type I [7]. The overall proteoglycan composition of the NP is reduced and altered by decreased synthesis of aggrecan and increased synthesis of versican, decorin and biglycan, thus resulting in reduced water binding capacity and a consequential decreased hydration of the extracellular matrix within the NP [21,22]. Concurrently matrix degradation is accelerated by the upregulation of MMPs (Matrix Metalloproteinases) and ADAMTS (A Disintegrin And Metalloproteinase With Thrombospondin Motifs) [23,24]. Compositional changes in the matrix during IVD degeneration is also accompanied by cellular changes with increased apoptosis [25,26] and senescence [19,27,28] displayed by NP cells, together with decreased tissue cellularity and viability of remaining disc cells [19,29].

The cells of the IVD produce a plethora of catabolic cytokines and chemokines [30-40] with highest expression seen in the NP and inner AF [30,33], expression within the outer AF is differentially expressed, with posterior AF tissue displaying higher expression of cytokines than the anterior AF [38]. There is increasing evidence supporting the role of a pivotal cytokine: Interleukin (IL)-1 in the pathogenesis of...
tissue engineering has produced a magnitude of biomaterial scaffolds with improving resemblance both structurally and mechanically to the native NP, thus the development of a non-degradable biomaterial which mimics the functional biological matrix enough to provide the correct biomechanics may render the use of cells unnecessary. This review discusses the potential future treatment strategies of IVD degeneration including the use of cells or biomaterials, used individually or in combination, in order to answer the question: what is the ideal strategy for IVD degeneration?

Cells Alone for Disc Degeneration

The choice of cells to be used in IVD regeneration must be carefully considered to ensure successful therapeutic outcome. The implanted cells would need to meet certain requirements for adoption into clinical practice: they should be easily sourced and available in sufficient numbers to repopulate the NP; cells should be autologous where possible to minimise immunogenic risk and be capable of regenerating the correct biological matrix in order to functionally replicate disc metabolism and biomechanics [75]. The safety, effectiveness and viability of the cells must also be thoroughly characterised within the hypoxic and acidic disc microenvironment.

The use of autologous NP cells would be the ideal strategy and a variety of studies have shown them to be successful; both biologically to regenerate the NP matrix and clinically to reduce pain [76-78]. Transplanted disc derived chondrocytes injected into degenerated IVDs of dogs were found to maintain retention of disc height and promote proteoglycan and collagen type II deposition [76]. Furthermore patients treated with autologous disc cell transplantation following discectomy, as part of the Euro Disc Randomised Trial, reported pain reduction after two years, in comparison to patients who did not receive autologous disc cell transplantation [76]; however, due to a lack of follow up on these patients, the long term effectiveness of this treatment cannot be accurately assessed. Furthermore, due to the low NP tissue cellularity, the harvesting of NP cells from more than one disc or in vitro expansion of cells for several weeks would be required to obtain a sufficient number of viable cells for transplantation. The use of autologous NP cells extracted from degenerate discs may also be inappropriate for regenerative purposes due to the increased expression of catabolic factors [37], decreased synthesis of normal matrix components and increased senescence displayed by these cells [19]. Finally the needle puncture which is currently used to extract autologous NP cells, has been shown to accelerate degenerative changes [79-81]. Non-autologous cell sources such as notochordal cells have also been investigated as potential candidates for NP regeneration [82,83]. Recently Potier et al., (2014) showed that notochordal cell-rich nucleus pulposus tissue stimulates matrix production by bone marrow stromal cells and NP cells, combined with increased NP cell proliferation and expression of NP phenotypic genes, thus promoting NP regeneration [84]. Despite this, the use of notochordal cells raises concerns regarding the allogeneic source required [11], the low cellular abundance [85], which may be insufficient to accommodate cell transplantation and a lack of understanding as to whether notochordal cells can differentiate into a biologically functioning NP cell [86].

Stem cells, particularly human Mesenchymal Stem Cells (hMSC) are an attractive cell choice for IVD regeneration since they can be extracted from a variety of adult tissues [87], they have proliferative capacity, have the ability to differentiate into multiple cell lineages [88] and avoid the ethical issues surrounding the use of embryonic stem
<table>
<thead>
<tr>
<th>Hydrogel Scaffold Material for NP</th>
<th>Culture conditions</th>
<th>Cellular or Acellular</th>
<th>Key Findings</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gelatin hydrogel microspheres</td>
<td>In vivo (rabbit)</td>
<td>Acellular with platelet-rich plasma.</td>
<td>Suppression of degeneration. Proteoglycan production in NP and inner AF.</td>
<td>[60]</td>
</tr>
<tr>
<td>Ionic Methacrylated gellan gum- (IGG-MA) and photo-crosslinked (phGG-MA) hydrogels</td>
<td>In vitro</td>
<td>Acellular and human Intervertebral Disc (hIVD) cells encapsulated. Mechanical properties of cell-laden hydrogels increased in comparison to acellular hydrogels.</td>
<td>Encapsulated cells found to be viable up to 21 days of culturing. In vivo a thin fibrous capsule was observed around implanted hydrogels. No evidence of necrosis, calcification, and acute inflammatory reaction. Apoptosis observed in phGG-MA. Evidence of chondrogenesis following subcutaneous implantation of iGG-MA.</td>
<td>[61] [62] [63]</td>
</tr>
<tr>
<td>Atelocollagen® gel</td>
<td>In vivo: Rabbit.</td>
<td>Rabbit MSCs</td>
<td>Degenerated discs of MSC-transplanted group regained a disc height value of about 91% compared to normal controls. Proteoglycan production confirmed by histological and immunological evaluation.</td>
<td>[64]</td>
</tr>
<tr>
<td>Alginate</td>
<td>In vitro under hypoxia (2%) and normoxia (20%)</td>
<td>Rat MSCs with transforming growth factor-β1</td>
<td>Hypoxia induced upregulation of Glucose transporter-3, matrix metalloproteinase-2, collagen type II and type XI, and aggrecan mRNA and protein expression was upregulated. Transforming growth factor-β1 treatment increased MAPK activity and Sox-9, aggrecan, and collagen type II gene expression.</td>
<td>[65]</td>
</tr>
<tr>
<td>Photocrosslinked alginate</td>
<td>In vitro and In vivo (murine subcutaneous model)</td>
<td>Bovine NP cells</td>
<td>Production of aggrecan and collagen type II. Cellular hydrogels were mechanically superior to acellular hydrogels. Young's modulus of cellular hydrogels significantly increased from 4 to 8 weeks.</td>
<td>[66]</td>
</tr>
<tr>
<td>Type II collagen and Hyaluronic Acid (HA).</td>
<td>In vitro</td>
<td>Rat MSCs with and without differentiating medium.</td>
<td>Increased aggrecan and collagen type II with decreased collagen I in hydrogels constructs where differentiating medium used.</td>
<td>[67]</td>
</tr>
<tr>
<td>Hyaluronan gel (Durolane®), hydrogel (Puramatrix®), and tissue-glue gel (TISSEEL®)</td>
<td>In vivo mini pigs</td>
<td>Human Mesenchymal Cells (hMSCs), IVD cells (hDCs), and Chondrocytes (hCs)</td>
<td>Xenotransplanted hMSCs and hCs survived in porcine IVDs for 6 months and produced collagen II in all six animals. Following six months pronounced endplate changes, and bone mineralisation indicating severe IVD degeneration were observed within all cellular and acellular hyaluronan gel carrier groups.</td>
<td>[68]</td>
</tr>
<tr>
<td>Chitosan-GLycerophosphate (GI- Gp) hydrogel</td>
<td>In vitro</td>
<td>Human MSCs in standard medium.</td>
<td>Production of proteoglycans and collagens in a ratio which more closely resembles that of NP cells than articular chondrocytes.</td>
<td>[69]</td>
</tr>
<tr>
<td>Hyaluronan-poly (N-isopropyl- lacrylamide) hydrogel.</td>
<td>In vitro</td>
<td>Bovine NP cells</td>
<td>All HA, HA-pNIPAM and their degradation products were cytocompatible to NP cells. Glycosaminoglycan synthesis was similar in HA-pNIPAM and alginate gels. Higher expression of hyaluronan synthases and lower expression of COLI and COLII mRNA were noted in cells cultured in HA-pNIPAM. Higher GAG/DNA ratio and higher collagen type II, SOX9, cytokeratin-19, cluster of differentiation 24, and forkhead box protein F1 expressions were found for hMSCs cultured in HA-pNIPAM compared with those cultured in alginate. Ex vivo, direct combination of HA-pNIPAM with the disc environment induced a stronger disc-like differentiation of hMSCs than predifferentiation of hMSCs followed by their delivery to the discs.</td>
<td>[70] [71]</td>
</tr>
<tr>
<td>photo-curable (pHEMA-co-APMA grafted with Polyamidoamine (PAA))</td>
<td>In vitro</td>
<td>hMSC with standard and chondrogenic differentiating medium.</td>
<td>Elevated expression levels of aggrecan and collagen II when cultured in chondrogenic media under hypoxic conditions, in comparison with culture in hMSC media for 14 days. Significant decrease in stiffness and modulus values of cellular hydrogels in comparison with acellular hydrogels at both day 7 and day 14. Increasing cytotoxicity with increasing UV exposure time.</td>
<td>[72]</td>
</tr>
</tbody>
</table>
cells. A number of hMSC sources have been investigated including bone marrow, periosteum, synovial membrane and adipose tissue [89-91]. Studies have suggested that the source of MSCs are critical to the clinical outcome with improved expansive and chondrogenic differentiation potential for cartilage repair in synovial membrane and adipose tissue derived MSCs in comparison to bone marrow derived MSCs [87-92]. Recently, autologous bone marrow derived MSCs have been demonstrated as a potential side-effect of this therapeutic process [98-100]. Despite limited publications on the use of MSCs alone for the regeneration of the IVD, successful outcomes have been reported, particularly in small animal models where transplanted bone marrow derived MSCs have been shown to undergo chondrogenesis with consequential deposition of proteoglycans and collagen type II in both rabbit IVD [97] and rat coccygeal discs [101]. Similarly expression of discogenic genes with matrix staining for aggrecan and collagen type II occurred where hMSCs were injected into an explant NP tissue model [102].

The success of hMSCs alone for the regeneration of the IVD in small animal models, has not always been replicated in large animal models. Henriksson et al., (2009) investigated the survival and differential capacity of hMSCs into injured porcine discs both alone and with a hydrogel carrier [103]. hMSCs were shown to survive and express typical chondrogenic markers, but immunopositivity for aggrecan and collagen type II was only observed in cell/hydrogel discs. Furthermore, low cell survival and the formation of a collagen type I/II scar tissue has been reported following 3 months after in vivo injection of allogenic disc derived MSCs [104]. Collectively these results suggest that transplantation of cells alone into a large animal model is not sufficient to produce the correct functional matrix, possibly due to the larger disc size giving a greater nutrient diffusion distance, inducing nutrient deprivation for the transplanted cells. Furthermore concerns, regarding MSC leakage following injection, with consequential undesirable bone formation, has been demonstrated as a potential side-effect of this therapeutic strategy, thus highlighting the potential need for cell carrier systems or annulus-sealing technologies to avoid the pitfalls of this treatment approach [105]. Despite this, results from a small human trial, whereby 10 patients with disc degeneration but intact annulus fibrosus, received an injection of autologous expanded bone marrow derived MSCs, reported significant improvements in pain and disability 12 months following treatment [96]. However these patients demonstrated no evidence of improved disc height [86]. These results suggest that the use of hMSCs transplanted into the IVD alone has limitations but may be improved with the use of an appropriate biomaterial scaffold.

The major drawback of MSC based strategies is a lack of understanding of the normal NP cell phenotype. The majority of studies, including those which have been discussed in this review, define NP cell differentiation using traditional chondrogenic genes such as Sex Determining Region (SRY) box 9, collagen type II and aggrecan [94,102,106,107]. However cells and tissues of articular cartilage and NP demonstrate significant differences in terms of morphology, ECM disposition and biomechanical behaviour [5]; consequently, the identification of differential NP markers which can be used to inform and thoroughly assess MSC differentiation is the current focus of many research studies [14-18,108].

Acellular Biomaterials for Disc Degeneration

Acellular biomaterial scaffolds provide a more simplistic therapeutic alternative to cellular strategies without the added complications of cell harvesting. Similar to cellular strategies, an increasingly prevalent issue with acellular strategies is whether one acellular treatment will accommodate all stages of degeneration. Based on trends in current research, one design strategy for acellular treatments could include non-invasive injectable monophasic hydrogels combined with inhibitors of degeneration or growth factors during early stages of degeneration to repair the NP [60], injectable biphasic scaffolds to repair the NP and AF in mid stages of degeneration and Tissue Engineered Total Disc Replacements (TE-TDR) in severely degenerate cases [109].

The use of hydrogels as delivery systems of catabolic inhibitors and growth factors to provide an acellular treatment strategy for NP repair has been successfully reported [60,110-112]. It must be noted however that a recent focus on the use of hydrogels as delivery systems for both cells and biomolecules is evident, thus the effectiveness of catabolic inhibitors and/or growth factors alone within monophasic scaffolds to repair the NP has not been thoroughly assessed. There is a clear rationale for this however since a regenerative source would need to be combined with mediators to inhibit degeneration to fully restore normal disc function.

The main challenge in the development of monophasic acellular hydrogels for the treatment of IVD degeneration is ensuring sufficient mechanical properties to withstand the load forces exerted on the spinal column. Silva-Correia et al., (2013) investigated the mechanical properties of acellular and cell laden ionic- and photo-crosslinked methacrylated gellan gum hydrogels; mechanical integrity of acellular hydrogels was maintained throughout the 21 day culture period, however cell-laden hydrogels were mechanically superior [61].

<table>
<thead>
<tr>
<th>Hydrogel</th>
<th>In vitro</th>
<th>Rabbit NP cells</th>
<th>Increased gene expression of aggrecan and type II collagen and increased glycosaminoglycan production in NP cells cultured in the hydrogel in comparison to monolayer controls.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chitosan/Gelatin/B-Glycerol Phosphate (C/G/GP) disodium salt hydrogels</td>
<td>In vitro</td>
<td>Rabbit NP cells</td>
<td>Up-regulation of MMP-3 and up-regulation aggrecan and type II collagen in mRNA level. The sulfated-glycosaminoglycan production was increased and the apoptosis was inhibited in the post-treatment group.</td>
</tr>
</tbody>
</table>

Table 1: Hydrogels used for NP regeneration.

Total Disc Replacement (TDR), which consists of polyethylene on metal, or metal on metal implants engineered to resemble a low friction ball and socket joint, is currently considered as an alternative treatment strategy to spinal fusion [113]. This method does not avoid invasive surgery since the excision of the degenerate disc is unavoidable, however does restore some mobility to the intervertebral joint which could reduce the risk of adjacent disc degeneration [114]. Considerable debate as to whether TDR is more efficacious than spinal fusion still remains. A Cochrane review [114] systematically assessed the efficacy outcomes of TDR in terms of motion preservation, adjacent disc degeneration and patient satisfaction and concluded that no evidence of superior clinical outcomes between TDR and spinal fusion was observed. Furthermore the authors of this review advised that caution should be taken when considering the adoption of TDR into wide scale clinical practice since the effectiveness of TDR is patient dependent and complications may arise years following treatment [114]. Despite this, Siepe et al., (2010) conducted a 5-10 year follow up of patients whom had undergone TDR as treatment for disc degeneration and concluded that TDR was a viable treatment alternative to spinal fusion [115]. It is clear that both spinal fusion and TDR have limitations, however the development of novel polymeric implants which replicate the biomechanics of the natural disc could be considered as an effective acellular strategy, particularly in severe stages of degeneration, where the use of monophasic biomaterials or cells alone would be insufficient to provide the biological functions of all anatomical regions of the IVD. In particular novel viscoelastic TDR materials have been developed which replicate the flexibility, stiffness and stress/stain dynamics of native disc, thus could be used as a more mechanically efficacious implant material for TDR in the future [109,116].

Despite the development of novel polymeric materials which could be used as a single material implant for TDR, more effective outcomes may be achieved with a Tissue Engineered (TE) strategy, including a combination of biomaterials in order to effectively replicate the total IVD (NP, AF, CEP). To date, biphasic scaffolds, seeded with cells, have shown potential for regeneration of two of the anatomical regions of the IVD (NP and AF) [117,118]. Furthermore, calcium polyphosphate substrates have been used to engineer cartilaginous end plates [119,120]. The success of combining multiple biomaterials as an effective acellular strategy is dependent on replicating the correct biomechanical properties of the NP, AF and CEP A TE-TDR which replicates all three anatomical regions is yet to be developed, however the studies discussed here demonstrate clear progression in the aim to develop a functional spinal unit.

**Cellular Biomaterials for Disc Degeneration**

As discussed, the use of cells alone or acellular biomaterials for disc repair, individually have shown some success for the treatment of IVD degeneration, both, however provide different clinical outcomes, such as the regenerative capacity provided by the use of cells and the mechanical support provided by acellular biomaterial scaffolds; consequently current research has focused on the use of cellular biomaterial scaffolds (Table 1) which provide biomechanical support whilst simultaneously regenerating the NP matrix, thus resulting in an integrated and biologically functioning tissue. The ideal load bearing biomaterial scaffold for IVD regeneration, which meets all requirements in terms of biocompatibility, bioactivity, mechanical properties and injectability, is yet to be produced. However a limited number of studies have demonstrated success in terms of hMSC encapsulation and differentiation towards the NP lineage. Traditionally the biocompatibility of natural polymer scaffolds has been an appealing choice for NP repair, including collagen [121], alginate [65], gelatine [60], hyaluronan [67,68], chitosan-glycerophosphate [94,107] and thermoresponsive hyaluronic acid (Table 1) [71]. However the use of natural polymers raises concerns regarding batch variation and immunogenic risk; consequently a number of studies have looked to develop synthetic polymer scaffolds which have the added advantage of synthesis control, large scale production and the ability to tailor bioactivity, mechanical properties and degradation rates. However toxic chemicals including initiators, stabilisers, organic solvents, cross linkers, emulsifiers and unreacted monomers which may be used in the synthesis and polymerisation of synthetic hydrogels pose a significant safety risk [64,122]. An ideal biomaterial scaffold, particularly in early stages of degeneration when it may not be necessary to excise the degenerate disc, would be an injectable hydrogel which delivers cells and biomolecules followed by in situ solidification; however this again poses significant challenges since potentially toxic unreacted material may need to be injected directly into the body, for this reason a variety of hydrogel systems with different fabrication techniques have been investigated [122]. Encapsulation and subsequent discogenic differentiation of MSCs has been performed in synthetic photo-crosslinked hydrogels, however apoptosis [63] and cytotoxicity with increasing UV exposure time [116] has been observed using this fabrication technique; thus raising concerns regarding the use of photocrosslinking not only to the implanted cells but also to surrounding tissues during delivery [72]. An alternative attractive to photo-crosslinked hydrogels is the use of thermo-reversible hydrogels which undergo liquid to gel transition at body temperature [71,73,123]. Studies have demonstrated successful biocompatibility, discogenic differentiation and deposition of an NP like matrix by MSCs cultured in thermo-responsive Chitosan-Glycerophosphate (C/Gp) hydrogels [94,124]. Further work by Cheng et al., (2013) showed sustained release of the antioxidant ferulic acid in thermosensitive Chitosan-Gelatin-Glycerol Phosphate hydrogels, with consequential reduction in catalytic mediators and increased synthesis of normal matrix components, thus could be combined with cells to enhance NP regeneration [74]. Alternatively the use of a thermo-reversible Hyaluronan-poly(N-Isopropylacrylamide) (HA-pNIPAM) hydrogel has been recently shown to induce discogenic differentiation of MSCs with production of an NP like matrix under hypoxic conditions [71,70].

The majority of cellular hydrogel systems have been designed for NP regeneration (Table 1) since this is the main region which undergoes significant cellular and matrix changes during degeneration of the IVD [19,20]. Despite this, NP repair is likely to be insufficient, particularly in severely degenerate cases where tears in the AF may result in extrusion of the implanted biomaterial and/or cells; consequently a variety of studies have investigated biphasic scaffolds which aim to repair the AF and NP simultaneously [118,125,126]. The use of electrospinning polymeric material has attracted significant interest in order to the replicate the highly organised native AF structure [127]. Lazebnik et al., (2011) used a biomimetic strategy by combining porcine chondrocyte cell seeded agarose gel surrounded by cell seeded electroporin polycaprolactine fibres and observed that cells were viable, well distributed and orientated themselves in the direction of the fibres [128]. Successful incorporation of growth factors to enhance regeneration has also been shown in electroporin scaffolds [129]. Furthermore, biphasic scaffolds consisting of a hydrogel NP centre surrounded by a polymeric electroporin AF
scaffold have been shown to possess superior mechanical properties [128,130].

Despite recent success of NP regeneration in vitro and in small animal models, there are still significant challenges that remain before such studies can be scaled up to pre-clinical analysis. Unresolved questions include: what is the ideal cell type and source? Is the use of a biomaterial scaffold necessary? At what stage of degeneration is regenerative cell therapy clinically applicable? Furthermore, Reitmeir et al., (2014) conducted an in vivo efficacy study whereby bone marrow derived MSCs were encapsulated within hydrogels, incorporated with anti-angiogenic factors and implanted into ovine disc; following 12 weeks no significant difference in biomechanical properties was observed between implanted and untreated discs and disc height and degeneration score deteriorated for all implant treated discs [131]. Thus caution should be taken when considering in vitro results since the complex molecular and biomechanical disc microenvironment makes replication of in vitro results in vivo extremely difficult.

**Personalized Therapies**

The recent advances in quantitative MRI imaging [132] may one day enable the clinician to identify early stages of degeneration which could be targeted by cell based therapies alone, whilst it is likely mid stage degeneration may require cells together with biomaterials. However, certain patients may not be suitable for cell based therapies and acellular approaches may be more suitable, such as those with end plate calcification. With the advent of specialist imaging modalities personalised therapies may become possible.

**Discussion and Future Outlooks**

When considering the most effective treatment for IVDD degeneration it is important to define and diagnose the IVDD by stage of degeneration. A multitude of hydrogel scaffolds for IVDD degeneration has been proposed each of which is competing to provide the ideal therapeutic strategy. It is clear however that one scaffold will not suffice; clinicians should be presented with a variety of treatment options, both cellular and acellular, in order deliver the most efficacious, safe and cost effective treatment for the stage of degeneration. In order to reduce the amount of current surgical practise on IVDD repair, which at present is clinically counter intuitive, scientific research into IVDD degeneration must remain at the forefront in order to bridge the gap between research therapeutics and adoption into clinical practise.

**References**


